U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07247227) titled 'Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC' on Nov. 17.
Brief Summary: This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.
Study Start Date: Oct. 10, 2023
Study Type: INTERVENTIONAL
Condition:
NSCLC
Intervention:
DRUG: Sugemalimab and Chemotherapy
Sugemalimab 1200mg plus 4-6 cycles of platinum-based chemotherapy as first-line therapy, followed by Sugemalimab 1200mg to 35 cycles, or until disease progression, or ICF withdrawn by participants, or death or unacce...